Tag Archives: Sumant Kulkarni

Zynerba Pharmaceuticals (ZYNE) Gets a Buy Rating from Canaccord Genuity

In a report issued on April 18, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $18.00. The company’s shares closed last Thursday at $4.51. According to TipRanks.com,

Canaccord Genuity Reaffirms Their Buy Rating on Zynerba Pharmaceuticals (ZYNE)

In a report issued on April 18, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $18.00. The company’s shares closed last Thursday at $4.51. According to TipRanks.com,

Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Forma Therapeutics Holdings (FMTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurocrine (NBIX – Research Report), Forma Therapeutics Holdings (FMTX – Research Report) and EDAP TMS (EDAP – Research Report) with bullish sentiments.

Analysts Are Bullish on These Healthcare Stocks: Zynerba Pharmaceuticals (ZYNE), Beyondspring (BYSI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (ZYNE – Research Report) and Beyondspring (BYSI – Research Report) with bullish sentiments. Zynerba Pharmaceuticals (ZYNE) In a report issued

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

In a report issued on December 22, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $14.00. The company’s shares closed last Tuesday at $8.69. According to TipRanks.com,

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (NASDAQ: ITCI) and Ascendis Pharma (NASDAQ: ASND)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intra-Cellular Therapies (ITCI – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments. Intra-Cellular Therapies (ITCI) In a report